 |
|
Microchip-based device can detect rare tumor cells in bloodstream
December 20, 2007A team of investigators from the Massachusetts General Hospital (MGH) Biomicroelectromechanical Systems (BioMEMS) Resource Center and the MGH Cancer Center has developed a microchip-based device that can isolate, enumerate and analyze circulating tumor cells (CTCs) from a blood sample. CTCs are viable cells from solid tumors carried in the bloodstream at a level of one in a billion cell. Because of their rarity and fragility, it has not been possible to get information from CTCs that could help clinical decision-making, but the new device - called the "CTC-chip,"- has the potential to be an invaluable tool for monitoring and guiding cancer treatment.
"This use of nanofluidics to find such rare cells is revolutionary, the first application of this technology to a broad, clinically important problem," says Daniel Haber, MD, director of the MGH Cancer Center and a co-author of the report in the December 20 issue of Nature. "While much work remains to be done, this approach raises the possibility of rapidly and noninvasively monitoring tumor response to treatment, allowing changes if the treatment is not effective, and the potential of early detection screening in people at increased risk for cancer."
The existence of CTCs has been known since the mid-19th century, but since they are so hard to find, it has not been possible to adequately investigate their biology and significance. Microchip-based technologies have the ability to accurately sense and sort specific types of cells, but have only been used with microliter-sized fluid samples, the amount of blood in a fingerprick. Since CTCs are so rare, detecting them in useful quantities requires analyzing samples that are 1,000 to 10,000 times larger.
To meet that challenge the MGH BioMEMS Resource Center research team - led by Mehmet Toner, PhD, senior author of the Nature report and director of the center in the MGH Department of Surgery, and Ronald Tompkins, MD, ScD, chief of the MGH Burns Unit and a co-author - first investigated the factors required for microchip analysis of sufficiently large blood samples. The device they developed utilizes a business-card-sized silicon chip, covered with almost 80,000 microscopic posts coated with an antibody to a protein expressed on most solid tumors. The researchers also needed to calculate the correct speed and force with which the blood sample should pass through the chip to allow CTCs to adhere to the microposts.
"We developed a counterintuitive approach, using a tiny chip with critical geometric features smaller than a human hair to process large volumes of blood in a very gentle and uniform manner - almost like putting a 'hose' through a microchip," explains Toner.
Several tests utilizing cells from various types of tumors verified that CTCs were captured by posts covered with the antibody 'glue.' Even tumor cells expressing low levels of the target protein and samples containing especially low levels of CTCs were successfully analyzed by the CTC-chip. In contrast to current technology for detecting CTCs, the new microchip device does not require any pre-processing of blood samples, which could damage or destroy the fragile CTCs.
The researchers then tested the CTC-chip against blood samples from 68 patients with five different types of tumors - lung, prostate, breast, pancreatic and colorectal. A total of 116 samples were tested, and CTCs were identified in all but one sample, giving the test a sensitivity rating of 99 percent. No CTCs were found in samples from cancer-free control volunteers. To evaluate the device's ability to monitor response to treatment, blood samples were taken from nine cancer patients during their treatment for lung, colorectal, pancreatic or esophageal tumors. Changes in levels of CTCs accurately reflected changes in tumor size as measured by standard CT scans.
"We looked at four major cancer killers and were able to consistently find these cells and correlate test results with traditional monitoring techniques," Toner says. "Some of these tumors have several potential drugs to choose from, and the ability to monitor therapeutic response in real time with this device - which has an exquisite sensitivity to CTCs - could rapidly signal whether a treatment is working or if another option should be tried."
CTCs also can provide the molecular information needed to identify tumors that are candidates for the new targeted therapies and should help researchers better understand the biology of cancer cells and the mechanisms of metastasis. Considerable work needs to be done before the CTC-chip is ready to be put to clinical use, and the MGH investigators are establishing a Center of Excellence in CTC Technologies to further explore the potential of the device, which also has been licensed to a biotechnology company for commercial development.
Massachusetts General Hospital
To meet that challenge the MGH BioMEMS Resource Center research team - led by Mehmet Toner, PhD, senior author of the Nature report and director of the center in the MGH Department of Surgery, and Ronald Tompkins, MD, ScD, chief of the MGH Burns Unit and a co-author - first investigated the factors required for microchip analysis of sufficiently large blood samples. The device they developed utilizes a business-card-sized silicon chip, covered with almost 80,000 microscopic posts coated with an antibody to a protein expressed on most solid tumors. The researchers also needed to calculate the correct speed and force with which the blood sample should pass through the chip to allow CTCs to adhere to the microposts.
"We developed a counterintuitive approach, using a tiny chip with critical geometric features smaller than a human hair to process large volumes of blood in a very gentle and uniform manner - almost like putting a 'hose' through a microchip," explains Toner.
Several tests utilizing cells from various types of tumors verified that CTCs were captured by posts covered with the antibody 'glue.' Even tumor cells expressing low levels of the target protein and samples containing especially low levels of CTCs were successfully analyzed by the CTC-chip. In contrast to current technology for detecting CTCs, the new microchip device does not require any pre-processing of blood samples, which could damage or destroy the fragile CTCs.
The researchers then tested the CTC-chip against blood samples from 68 patients with five different types of tumors - lung, prostate, breast, pancreatic and colorectal. A total of 116 samples were tested, and CTCs were identified in all but one sample, giving the test a sensitivity rating of 99 percent. No CTCs were found in samples from cancer-free control volunteers. To evaluate the device's ability to monitor response to treatment, blood samples were taken from nine cancer patients during their treatment for lung, colorectal, pancreatic or esophageal tumors. Changes in levels of CTCs accurately reflected changes in tumor size as measured by standard CT scans.
"We looked at four major cancer killers and were able to consistently find these cells and correlate test results with traditional monitoring techniques," Toner says. "Some of these tumors have several potential drugs to choose from, and the ability to monitor therapeutic response in real time with this device - which has an exquisite sensitivity to CTCs - could rapidly signal whether a treatment is working or if another option should be tried."
CTCs also can provide the molecular information needed to identify tumors that are candidates for the new targeted therapies and should help researchers better understand the biology of cancer cells and the mechanisms of metastasis. Considerable work needs to be done before the CTC-chip is ready to be put to clinical use, and the MGH investigators are establishing a Center of Excellence in CTC Technologies to further explore the potential of the device, which also has been licensed to a biotechnology company for commercial development.
Massachusetts General Hospital
Tumor Cell News and Current Tumor Cell Events RSSUAB Anti-Cancer Research Featured in Scientific American
Scientific American magazine focused on two University of Alabama at Birmingham (UAB) Comprehensive Cancer Center researchers in a news story on experimental next-generation anti-cancer therapies.
Nanoparticles + light = dead tumor cells
Medical physicists at the University of Virginia have created a novel way to kill tumor cells using nanoparticles and light.
Erectile dysfunction drugs allowed more chemotherapy to reach brain tumors in laboratory study
In a study using laboratory animals, researchers found that medications commonly prescribed for erectile dysfunction opened a mechanism called the blood-brain tumor barrier and increased delivery of cancer-fighting drugs to malignant brain tumors.
Novel structure proteins could play a role in apoptosis
Isoforms from Novel Structure Proteins (NSP), a new family of genes discovered by researchers in the Sbarro Institute for Cancer Research and Molecular Medicine in Temple University's College of Science and Technology, could be involved in apoptosis or programmed cell death.
Counting tumor cells in blood predicts treatment benefit in prostate cancer
Counting the number of tumor cells circulating in the bloodstream of patients with castration-resistant prostate cancer can accurately predict how well they are responding to treatment, new results show.
Refusal of suicide order: Why tumor cells become resistant
Cells with irreparable DNA damage normally induce programmed cell death, or apoptosis. However, this mechanism often fails in tumor cells so that transformed cells are able to multiply and spread throughout the body.
New Cancer Treatment Targets Both Tumor Cells and Blood Vessels
It takes more than one punch to fight tumors. Often, tumors have more than one way of surviving, and attacking the tumor alone is not enough.
Experimental anti-cancer synthetic molecule targets tumor cell growth and angiogenesis
A recent study conducted by three French CNRS (Centre National de la Recherche Scientifique) laboratories describes a new candidate anti-cancer drug, named HB-19.
Brown Chemists Create Cancer-Detecting Nanoparticles
A team led by a Brown University chemist has created the smallest iron oxide nanoparticles to date for cancer detection by magnetic resonance imaging (MRI). The magnetic nanoparticles operate like tiny guided missiles, seeking and attaching themselves to malignant tumor cells. Once they bind, the particles emit stronger signals that MRI scans can detect.
USC stem cell study sheds new light on cell mechanism
Research from the University of Southern California (USC) has discovered a new mechanism to allow embryonic stem cells to divide indefinitely and remain undifferentiated.
More Tumor Cell News Articles
 | Salivary Gland Cytopathology (Essentials in Cytopathology) by William C. Faquin, Celeste N. Powers Salivary gland cytopathology is one of the most challenging areas of diagnostic cytology. Salivary Gland Cytopathology will use a simplified algorithmic approach based upon differential diagnostic groups to cover practical aspects of diagnosing common as well as challenging salivary gland lesions. This volume published in the “Essentials in Cytopathology” book series will fulfill... |
 | Tumor Models in Cancer Research (Cancer Drug Discovery and Development) (Cancer Drug Discovery and Development) Beverly A. Teicher and a panel of leading experts comprehensively describe for the first time in many years the state-of-the-art in animal tumor model research. The wide array of models detailed form the basis for the selection of compounds and treatments that go into clinical testing of patients, and include syngeneic models, human tumor xenograft models, orthotopic models, metastatic models,... |
 | 21st Century Complete Medical Guide to Kidney Cancer (Renal Cell, Transitional Cell, Wilm¿s Tumor): Authoritative Government Documents and Clinical References for Patients and Physicians with Practical Information on Diagnosis and Treatment Options by PM Medical Health News This up-to-date and comprehensive CD-ROM provides a superb collection of official Federal government documents on kidney cancer: signs and symptoms, diagnosis, lab tests, treatment and management options, and ongoing clinical research. Every aspect of the disease is thoroughly covered. There is no other reference that is as fast, convenient, and portable - everything you need to know, from the... |
 | Cancer Cell Culture: Methods and Protocols (Methods in Molecular Medicine) (Methods in Molecular Medicine) Expert researchers describe in detail their most productive and up-to-date methods for growing cancer cells in the laboratory. There are methods to characterize and authenticate cell lines, to isolate and develop specific types of cancer cells, and to develop new cell line models. Functional assays are provided to evaluate clonogenicity, cell proliferation, apoptosis, adhesion, migration,... |
 | Diagnostic Cytogenetics (Springer Lab Manuals) In addition to the traditional cytogenetics still used as the basic methodology for everyday clinical diagnosis, new molecular cytogenetic techniques provide a useful basis for routine diagnosis. Flourescence in situ hybridization (FISH) has become a standard technique, and comparative genomic hybridization (CGH), spectral karyotyping (SKY), and multi-color FISH have shown their potential for... |
| Tumor Cell Heterogeneity: Origins and Implications. the Bristol-Myers Cancer Symposia, Volume Four. (Bristol-Myers cancer symposia) by Albert H. Owens, Donald S. Coffey, Stephen B. Baylin | |
 | Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal There is now a pressing need to discuss the already described and newly emerging mechanisms to see how they can be put together in more or less cohesive structure and how they can help to improve immune response to tumors. This monograph will, for the first time, present a comprehensive overview of different mechanisms of immune dysfunction in cancer as well as therapeutic approaches to their... |
 | Cancer Stem Cells: Novel Concepts and Prospects for Tumor Therapy (Ernst Schering Foundation Symposium Proceedings) Cancer stem cells werehave originally been identified in leukemia and later in several solid tumor types. They have very different properties from the bulk of the tumor, as they divide much more slowly and have very efficient drug- resistance mechanisms. Current treatments might largely spare cancer stem cells, thus leading to tumor recurrence and metastasis. The recent identification of growth... |
 | Analyzing T Cell Responses: How to analyze cellular immune responses against tumor associated antigens This book reviews, describes, categorizes and provides a critical assessment of all assays that have been used for the monitoring of antigen-specific immune responses. In particular, it emphasizes a global approach to the analysis of T cell mediated target/host interactions at the systemic and the peripheral level when such interactions are supposed to occur. The book, therefore, targets a... |
 | Innate and Adaptive Immunity in the Tumor Microenvironment (The Tumor Microenvironment) (The Tumor Microenvironment) Cancer cells are continuously interacting with the immune system of the host. These interactions can be regarded as a double edged sword. On the one hand, innate and adaptive immune responses act to protect the host by attempting rejection of the tumor. On the other hand, inflammatory cells and proteins stimulate multiplication and dissemination of cancer cells, thereby accelerating the... |
| © 2008 BrightSurf.com |